LPS O-antigen Serotyping for UTI Severity Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for urinary tract infections (UTIs) in pediatric patients are inadequate due to difficulties in distinguishing non-pathogenic from uropathogenic E. coli strains, leading to challenges in accurately diagnosing and managing UTIs, which can result in unnecessary antibiotic exposure and increased risk of renal scarring.
Innovation Solution
The method involves determining the predominant LPS O-antigen serotype in urine or fecal samples to identify febrile UTI LPS serotypes, correlating with the severity of clinical disease and potential for severe infection, allowing for targeted treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current clinical diagnostics are used to diagnose UTI, then diagnosis can be performed, but non-pathogenic from uropathogenic strains cannot be distinguished leading to inaccurate diagnosis
Solution Approach 1:
The invention segments the E. coli population by identifying specific LPS O-antigen serotypes (O2, O16, O25b) that are associated with febrile UTI and pyelonephritis. Instead of treating all E. coli as a single group, the method divides them into pathogenic segments (specific serotypes) and non-pathogenic segments, enabling accurate differentiation and precise diagnosis.
Solution Approach 2:
The invention uses LPS O-antigen serotyping as an intermediary marker to indirectly identify uropathogenic strains. Rather than directly detecting pathogenicity factors, the method employs LPS serotype identification as a mediator that correlates with clinical severity, enabling accurate strain differentiation through a reliable intermediate characteristic.
2Reliability
If antibiotic therapy is administered to all UTI cases, then treatment coverage is maximized, but unnecessary antibiotic exposure increases leading to resistance and health problems
Solution Approach 1:
The invention performs preliminary identification of LPS O-antigen serotypes before initiating antibiotic therapy. By pre-characterizing the bacterial strain's serotype, the system enables proactive decision-making about treatment necessity, allowing clinicians to avoid unnecessary antibiotics in cases where the serotype indicates low pathogenicity or alternative management approaches.
Solution Approach 2:
The invention changes the diagnostic parameter from general bacterial presence detection to specific LPS O-antigen serotyping. This parameter change provides granular information about bacterial pathogenicity potential, enabling differentiated treatment decisions that reduce unnecessary antibiotic exposure while maintaining appropriate treatment coverage for high-risk serotypes.
3Measurement precision
If culture proven diagnosis is used, then accurate identification is achieved, but days are needed for diagnosis delaying treatment
Solution Approach 1:
The invention extracts the specific diagnostic information needed (LPS O-antigen serotype) from the complex bacterial culture process. By focusing on detecting this particular molecular marker directly from clinical samples, the method bypasses the time-consuming steps of full bacterial culture and identification, achieving rapid serotyping within hours rather than days.
Solution Approach 2:
The invention replaces the mechanical culture-based identification system with a molecular detection system targeting LPS O-antigen serotypes. This substitution eliminates the need for prolonged bacterial growth and manual identification steps, enabling rapid automated detection of pathogenic serotypes while maintaining identification accuracy.
4Loss of information
If LPS serotyping is implemented, then severity prediction and targeted treatment are enabled, but diagnostic complexity increases
Solution Approach 1:
The invention makes the LPS serotyping methodology universal and applicable to routine clinical diagnostics. By developing assays that can be integrated into existing diagnostic workflows and using broadly applicable molecular techniques, the complex serotyping process becomes a standardized multi-functional tool that provides both identification and severity prediction information through a single test.
Data Source
AI summary
A method of identifying a subject having a urinary tract infection posing a significant risk of dangerous sequalae is described. The method includes obtaining a urine or fecal sample from the subject; determining the predominant LPS O-antigen serotype in the sample; and comparing the predominant LPS O-antigen serotype to a set of febrile UTI LPS serotypes. The method can also include treating the subject for UTI if the predominant O-antigen LPS serotype is a febrile UTI LPS serotype.